Axonex AI Group Limited

Axonex AI Group Limited

NNASDAQ:AXNX
0.99
USD
-0.08
(-7.22%)
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
- -
0.01
0.1
0.48
3.02
4.19
5.86
7.46
8.58
Basic EPS, GAAP
-0.95
-0.97
-4.64
-2.8
-1.48
-1.86
-1.28
-0.12
-0.11
Free Cash Flow per Basic Share
-0.96
-1.03
-4.66
-2.97
-2.34
-1.15
0.02
-0.11
0.11
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-2.67
-3.61
-14.24
-6.29
-6.34
-7.3
-8.02
-7.75
-7.8
Tangible Book Value per Share
-2.01
-1.93
20.41
6.4
7.77
6.28
8.34
9.31
9.56
Basic Weighted Avg Shares
18
19
7
29
37
43
47
49
50
Sales/Revenue/Turnover
- -
- -
1
14
112
180
274
366
432
Operating Margin (%)
- -
-14,198.44
-4,545.54
-583.21
-48.2
-35.86
-15.49
-1.29
-1.67
Depreciation Expense
1
1
1
1
2
9
12
12
12
Net Income, GAAP
-17
-18
-32
-80
-55
-80
-60
-6
-6
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
17.39
Profit Margin (%)
- -
-14,110.16
-4,594.48
-578.4
-49.24
-44.41
-21.81
-1.66
-1.31
Working Capital
7
25
159
200
282
294
400
446
461
LT Debt
- -
- -
23
25
9
9
8
26
30
Total Equity
-36
-35
143
183
287
482
570
638
664
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
0.4
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
1
2
3
LT Borrowings
- -
- -
- -
LT Finance Leases
30
30
30
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
51
Market Capitalization
3,425
3,355
3,505

Working Capital

USD

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
482
512
526
Cash, Cash Equivalents & STI
333
343
345
Accounts Receivable, Net
51
57
63
Inventories
93
105
114
Total Current Liabilities
48
57
64
Payables & Accruals
31
30
26
ST Debt
1
2
3
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
36.53%
11.83%
Free Cash Flow
- -
-131.48%
-675%
Net Income, GAAP
- -
9.07%
-89.8%
Sales/Revenue/Turnover
- -
541.82%
33.86%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
48
69
70
86
274
2023
71
93
93
110
366
2024
91
115
116
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.5
-0.47
-0.34
0.01
-1.28
2023
-0.19
-0.15
0.08
0.13
-0.12
2024
-0.38
0.14
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

CEO
Hoi Lung Chan
Full Time Employees
36
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
Wing Kwok Centre Hong Kong Hong Kong
IPO Date
Jan 10, 2025
Business
Axonics, Inc. (NASDAQ: AXNX) develops and commercializes innovative sacral neuromodulation devices for the treatment of bladder and bowel dysfunction. The company offers the Axonics r15™ System, a rechargeable sacral neuromodulation device featuring MRI-compatible leads and a small, long-lasting implantable neurostimulator with up to 15 years of battery life; the Axonics F15™ System, a recharge-free sacral neuromodulation platform designed for patient convenience with five-year battery longevity; and related physician and patient mobile applications for remote monitoring and therapy management. Axonics primarily serves urologists, urogynecologists, and colorectal specialists treating patients with overactive bladder, urinary retention, and fecal incontinence in the United States, Europe, and select international markets. Founded in 2013 and headquartered in Irvine, California, the company focuses on the medtech segment of the healthcare industry, emphasizing minimally invasive therapies for chronic pelvic floor disorders. In recent developments, Axonics continues to expand its commercial footprint following FDA approvals for its second-generation systems and ongoing clinical studies supporting broader indications.

Company News

  • Axonex AI Group Limited Announces 2-for-5 Reverse Stock Split

  • Axonex AI Group Joins FLAIR's Embodied AI International Applications Hub and Launches Education Humanoid TOMO

  • Axonex AI Group Limited (NASDAQ: AXNX) Solidifies Transformation into an AI and Robotics-Focused Company

  • Boston Scientific Stock Set to Gain From Completion of Axonics Deal

  • Boston Scientific Closes Acquisition of Axonics, Inc.

  • Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates

  • Axonics Shares Fall Despite Australia's Approval for R20 SNM Device

  • Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia

  • Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic

  • Axonics Prevails in Patent Infringement Lawsuit with Medtronic

  • Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates

  • Axonics, Inc. (NASDAQ:AXNX) Shares Sold by Amalgamated Bank

  • Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia

  • Axonics Reports First Quarter 2024 Financial Results

  • Boston Scientific Announces Results for First Quarter 2024

  • FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal

  • All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy

  • Axonics Stockholders Approve Merger Agreement with Boston Scientific

  • Axonics Provides Update on Inter Partes Review Proceedings

  • Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System